Sanofi VaxRabeo Wins European Commission Approval as Next-Generation Rabies Vaccine for All Ages

Sanofi VaxRabeo has secured European Commission approval as a next-generation rabies vaccine for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) in all age groups. Sanofi announced the decision from Paris on November 19, 2026. The authorisation covers VaxRabeo (rabies virus inactivated strain Wistar) and is the first marketing authorisation approval for the product.

The approval follows a positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use on September 17, 2026. For public health teams and vaccine buyers, the Sanofi VaxRabeo decision adds a newer option alongside Sanofi’s current rabies vaccines, Verorab and Imovax Rabies. Readers tracking the sector can also follow our vaccine news coverage for related regulatory updates.

Thomas Triomphe, Head of Vaccines at Sanofi, called the approval a proud milestone that reflects the company’s commitment to rabies protection, built on five decades of expertise and innovation. He said “Death from rabies should be prevented at all costs,” adding that the vaccine brings a next-generation option to healthcare systems and patients.

Sanofi VaxRabeo Technology: Vero-Cell Manufacturing, Shelf Life and Thermostability

Sanofi VaxRabeo is manufactured using state-of-the-art Vero-cell technology. Sanofi says the vaccine is formulated to minimize the risk of allergic reactions and offers a longer shelf life than the company’s current rabies vaccines, along with improved thermostability. The table below summarizes the product profile exactly as disclosed by Sanofi.

AttributeDetail disclosed by Sanofi
Product nameVaxRabeo (rabies virus inactivated strain Wistar)
DeveloperSanofi
Approval bodyEuropean Commission
IndicationPre-exposure and post-exposure prophylaxis against rabies
Age groupsAll age groups
Manufacturing platformVero-cell technology
Shelf life60 months (five years)
Stability before reconstitutionUp to 27°C for 96 hours
Viral strainSame strain as Verorab and Imovax Rabies

The shelf-life data are among the most practical details in the announcement. VaxRabeo has a 60-month shelf life and maintains stability at temperatures up to 27°C for 96 hours before reconstitution. Those figures matter for clinics, travel health centres and national programmes that must store and move vaccines without interruption.

Advertisement

VaxRabeo shares the same viral strain as Verorab and Imovax Rabies, which Sanofi says have demonstrated safety and efficacy over more than five decades. It is indicated for PrEP and PEP in every age group and supports flexible schedules, including a reduced WHO-recommended two-dose PrEP regimen and a four-dose PEP regimen for unvaccinated individuals, given with or without rabies immunoglobulin.

Sanofi VaxRabeo Clinical Programme: PrEP and PEP Results

The European approval of Sanofi VaxRabeo rests on a comprehensive clinical programme. Sanofi compared the vaccine with its current standard-of-care vaccines, Verorab and Imovax Rabies, in both PrEP and PEP settings. The studies covered all age groups and WHO-recommended schedules, which gives regulators and clinicians a like-for-like view of performance.

In PrEP studies, two-dose and three-dose regimens of Sanofi VaxRabeo achieved protective antibody levels comparable to those of Verorab and Imovax Rabies in both adults and children. Booster doses given 12 months or 24 to 36 months after the last PrEP dose showed high boostability, which Sanofi says supports the lasting immunogenicity of the vaccine.

In PEP studies, the vaccine showed an immunogenicity profile similar to Sanofi’s current standard-of-care vaccines, with or without rabies immunoglobulins. Sanofi reports that 100% of participants achieved protective antibody levels intramuscularly. Across all studies, the safety profile was in line with existing vaccines, the vaccine was well tolerated, and no significant safety concerns were identified.

SettingComparatorReported outcome
PrEP (two-dose and three-dose regimens)Verorab, Imovax RabiesComparable protective antibody levels in adults and children
PrEP booster (12 or 24-36 months)Not disclosedHigh boostability
PEP (with or without immunoglobulins)Verorab, Imovax RabiesSimilar immunogenicity profile
PEP (intramuscular)Not disclosed100% of participants reached protective antibody levels
Safety (all studies)Existing vaccinesIn line with existing vaccines, no significant safety concerns

Why the Sanofi VaxRabeo Approval Matters for Global Rabies Prevention

Rabies is a viral zoonotic disease present in 150 countries, and the World Health Organization estimates it causes approximately 59,000 deaths worldwide each year. No treatment exists once clinical symptoms appear, and the disease is almost always fatal. It is preventable only through vaccination, combined with immunoglobulins in post-exposure prophylaxis. WHO also estimates that approximately 29 million people receive post-exposure vaccination annually. See the WHO rabies fact sheet for global context.

Advertisement

Transmission occurs mainly through the saliva of infected animals, with dogs responsible for most human cases through bites, scratches and contact with broken skin. Cats, bats, foxes, raccoons, skunks, jackals and mongooses can also transmit the virus. The burden falls heavily on children, because 40% of people bitten by suspect rabid animals are under 15 years of age. Preventable deaths continue, particularly in Asia and Africa.

Travel medicine is another use case highlighted in the release. Potential rabies exposure occurs in approximately 0.4% of travellers per month of stay in endemic regions, which makes pre-travel vaccination an important consideration. With a PrEP indication for all ages, Sanofi VaxRabeo gives European prescribers another authorised choice for travellers and at-risk groups. Our travel and infectious disease reports track similar developments.

Rabies metricFigure reported by Sanofi (citing WHO where stated)
Countries with rabies150
Estimated annual deaths worldwideApproximately 59,000
People receiving post-exposure vaccination each yearApproximately 29 million
Share of bite victims under 15 years40%
Traveller exposure riskApproximately 0.4% per month of stay
Main source of human casesDogs

Sanofi VaxRabeo Regulatory Timeline, Sources and Forward-Looking Statements

The regulatory path for Sanofi VaxRabeo moved from a CHMP positive opinion on September 17, 2026 to European Commission approval announced on November 19, 2026. Sanofi did not disclose a European launch date, pricing, reimbursement plans, manufacturing capacity or filings in other regions. Those items are labeled “Not disclosed” in the table below rather than estimated.

MilestoneDate or status
CHMP positive opinionSeptember 17, 2026
European Commission approvalAnnounced November 19, 2026
Launch timing in the EUNot disclosed
Pricing and reimbursementNot disclosed
Approvals outside the EUNot disclosed

Related Leads